Evaluation of Adiposity-Related Parameters in Obese Children

Authors: Mustafa M. Donma, Ahsen Yilmaz, Savas Guzel, Orkide Donma

Abstract:

The aim of the study was to evaluate possible relations among biochemical parameters thought to be related to adiposity-related mechanisms in children with normal body mass index (N-BMI), obese (OB) children, and children with metabolic syndrome (MetS). Weight, height, as well as waist, hip, head, and neck circumference values were taken and BMI values were calculated. Children aged 6-18 years were investigated. 176 children (44 children whose BMI percentiles between the 15th and 85th were classified as the control, 88 children with BMI percentiles above the 95th percentile were categorized as the OB group, and 44 children meeting the criteria for MetS were included in the MetS group) were surveyed in total. Serum leptin, ghrelin, adiponectin, asprosin, liver-expressed antimicrobial peptide 2 (Leap2), obestatin, and interleukin-6 levels were determined using ELISA. Statistical analyses were performed using SPSS for Windows. Leptin concentrations increased with the progression of obesity, while ghrelin concentrations showed a corresponding decrease. Interleukin-6, as a proinflammatory marker, increased in obese groups compared to those in the control group. Adiponectin appeared to be a parameter, did not significant potential for distinguishing OB children from those with MetS. In the MetS group, interleukin-6 was correlated with fasting blood glucose (FBG). Strong correlations were obtained among asprosin, Leap2, and obestatin in all groups. Strong correlations among asprosin, Leap2, and obestatin, suggesting their potential interrelation through various mechanisms in different metabolic phases. The association between FBG, as a key predictor of MetS, and interleukin-6 in the MetS group highlights the potential importance of including interleukin-6 in the list of MetS components.

Keywords: Adiposity, interleukin-6, metabolic syndrome, obese children.

References:

[1] D. Khanna, S. Khanna, P. Khanna, P. Kahar, and B. M. Patel, “Obesity: A chronic low-grade inflammation and its markers,” Cureus, vol. 14, no. 2, pp. e22711, Feb. 2022.
[2] M. Safaei, Sundararajan EA, Driss M, Boulila W, and Shapi'i A, “A systematic literature review on obesity: Understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity,” Comput. Biol. Med., vol. 136, pp. 104754, Sep. 2021.
[3] G. D. Miller, “Appetite regulation: Hormones, peptides, and neurotransmitters and their role in obesity,” Am. J. Lifestyle Med., vol.13, no. 6, pp. 586-601, Jun. 2017.
[4] R. H. Freire, and J. I. Alvarez-Leite, “Appetite control: hormones or diet strategies?,” Curr. Opin. Clin. Nutr. Metab. Care, vol. 23, no.5, pp. 328-335, Sep. 2020.
[5] A. Y. Yeung, and P. Tadi, “Physiology, Obesity Neurohormonal Appetite and Satiety Control,” (Updated 2020 Mar 14]. in: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2020 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555906/
[6] M. I. Wilasco, H. A. Goldani, C. T. Dornelles, R. L. Maurer, C. O. Kieling, et al, “Ghrelin, leptin and insulin in healthy children: Relationship with anthropometry, gender, and age distribution,” Regul. Pept., vol. 173, no. 1-3, pp. 21-26, Jan. 2012.
[7] D. Mishra, J. E. Richard, I. Maric, B. Porteiro, M. Häring, et al., “Parabrachial interleukin-6 reduces body weight and food intake and increases thermogenesis to regulate energy metabolism,” Cell Rep., vol. 26, no.11, pp. 3011-3026, Mar. 2019.
[8] M. Del Giudice, and S. W. Gangestad, “Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters,” Brain Behav. Immun., vol. 70, pp. 61-75, May 2018.
[9] H. Wang, T. Yang, Y. Shen, C. Wan, X. Li, et al., “Ghrelin inhibits interleukin-6 production induced by cigarette smoke extract in the bronchial epithelial cell via NF-κB pathway,” Inflammation, vol. 39, no. 1, pp. 190-198, Feb. 2016.
[10] J. V. Zhang, P. G. Ren, O. Avsian-Kretchmer, C. W. Luo, R. Rauch, et al., “Obestatin, a peptide encoded by the GHR gene, opposes GHR's effects on food intake,” Science, vol. 310, no. 5750, pp. 996-999, Nov. 2005.
[11] M. H. Eftekhari, M. Ranjbar-Zahedani, M. Basiratnia, A. Rezaianzadeh, and S. Faghih, “Comparison of appetite-regulating hormones and body composition in pediatric patients in predialysis stage of chronic kidney disease and healthy control group,” Iran. J. Med. Sci., vol.40, no. 1, pp. 27-33, Jan. 2015.
[12] B. K. Mani, N. Puzziferri, Z. He, J. A. Rodriguez, S. Osborne-Lawrence, et al., “LEAP2 changes with body mass and food intake in humans and mice,” J. Clin. Invest., vol. 129, no. 9, pp. 3909–3923, Sep. 2019.
[13] Z. B. Andrews, “The next big LEAP2 understanding ghrelin function,” J. Clin. Invest., vol.129, no. 9, pp. 3542-3544, Sep. 2019.
[14] A. Lacquaniti, V. Donato, V. Chirico, A. Buemi, M. Buemi, “Obestatin: an interesting but controversial gut hormone,” Ann. Nutr. Metab., vol. 59, no. 2-4, pp. 193-199, Dec. 2011.
[15] G. Pradhan, C. S. Wu, J. Han Lee, P. Kanikarla, S. Guo, et al., “Obestatin stimulates glucose-induced insulin secretion through ghrelin receptor GHS-R,” Sci. Rep., vol.7, no.1, pp. 979, Apr. 2017.
[16] J-H. Wang, H-Z. Li, X-X. Shao, W-H. Nie, Y-L. Liu, et al., “Identifying the binding mechanism of LEAP2 to receptor GHSR1a,” The FEBS Journal, vol. 286, no. 7, pp. 1332-1345, Apr. 2019.
[17] X. Ge, H. Yang, M. A. Bednarek, H. Galon-Tilleman, P. Chen, et al., “LEAP2 is an endogenous antagonist of the ghrelin receptor,” Cell Metab., vol. 27, no. 2, pp. 461-469.e6, Feb. 2018.
[18] M. A. Schalla, and A. Stengel, “LEAP2: A novel regulator of food intake and body weight?,” Nat. Rev. Gastroenterol. Hepatol., vol. 16, no.12, pp. 711-712, Dec. 2019.
[19] C. Duerrschmid, Y. He, C. Wang, C. Li, J. C. Bournat, et al., “Asprosin is a centrally acting orexigenic hormone,” Nat. Med., vol. 23, no.12, pp. 1444-1453, Dec. 2017.
[20] M. M. Donma, and O. Donma, “Asprosin: Possible target in connection with GHR and cytokine network expression in the post-burn treatment,” Med. Hypotheses, vol. 118, pp. 163-168, Sep. 2018.
[21] M. Yuan, W. Li, Y. Zhu, B. Yu, and J. Wu, “Asprosin: A novel player in metabolic diseases,” Front. Endocrinol. (Lausanne), vol. 11, pp. 64, Feb. 2020.
[22] World Health Organization (Internet). The WHO Child Growth Standards. Available from: http://www.who.int/childgrowth/en/ Accessed on June 10, 2016.
[23] P. Zimmet, K. G. Alberti, F. Kaufman, N. Tajima, M. Silink, et al, “The metabolic syndrome in children and adolescents- an IDF consensus report,” Pediatr. Diabetes., vol. 8, no. 5, pp. 299-306, Oct. 2007.
[24] S. Bellone, F. Prodam, S. Savastio, F. De Rienzo, I. Demarchi, et al., “Acylated and unacylated ghrelin levels in normal weight and obese children: influence of puberty and relationship with insulin, leptin and adiponectin levels,” J. Endocrinol. Invest., vol. 35, no. 2, pp. 191–197, Feb. 2012.
[25] K. J. Mackelvie, G. S. Meneilly, D. Elahi, A. C. Wong, S. I. Barr, et al., “Regulation of appetite in lean and obese adolescents after exercise: role of acylated and desacyl ghrelin,” J. Clin. Endocrinol. Metab., vol. 92, no. 2, pp. 648–654, Feb. 2007.
[26] L. Pacifico, C. Anania, E. Poggiogalle, J. F. Osborn, G. Prossomariti, et al., “Relationships of acylated and des-acyl ghrelin levels to bone mineralization in obese children and adolescents,” Bone, vol. 45, no. 2, pp. 274–279, Aug. 2009.
[27] M. RazzaghyAzar, M. Nourbakhsh, A. Pourmoteabed, M. Nourbakhsh, D. Ilbeigi, et al., “An evaluation of acylated ghrelin and obestatin levels in childhood obesity and their association with insulin resistance, metabolic syndrome, and oxidative stress,” J. Clin. Med., vol. 5, no. 7, pp. E61, Jun. 2016.
[28] H. L. Cheng, A. Sainsbury, F. Garden, M. Sritharan, K. Paxton, et al., “Ghrelin and peptide YY change during puberty: relationships with adolescent growth, development, and obesity,” J. Clin. Endocrinol. Metab., vol. 103, no. 8, pp. 2851–2860, Aug. 2018.
[29] J. Q. Purnell, D. S. Weigle, P. Breen, and D. E. Cummings, “Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans,” J. Clin. Endocrinol. Metab., vol. 88, no. 12, pp. 5747-5552, Dec. 2003.
[30] C. Langenberg, J. Bergstrom, G. A. Laughlin, and E. Barrett-Connor, “Ghrelin and the metabolic syndrome in older adults,” J. Clin. Endocrinol. Metab., vol. 90, no. 12, 6448-6453, Dec. 2005.
[31] L. Avila-Carrasco, M. A. Pavone, E. González, Á. Aguilera-Baca, R. Selgas, et al, “Abnormalities in glucose metabolism, appetite-related peptide release, and pro-inflammatory cytokines play a central role in appetite disorders in peritoneal dialysis,” Front. Physiol., vol. 10, pp. 630, May 2019.
[32] K. Timper, J. Denson, S. M. Steculorum, S. Rose-John, F. T. Wunderlich, et al, “CNS IL-6 trans-signaling is enhanced in obese mice to improve anorexigenic and glucoregulatory effects of IL-6,” Endocrine Abstracts, vol. 41, pp. OC5.4, 2016.
[33] F. Prodam, L. Trovato, I. Demarchi, A. Busti, A. Petri, et al, “Unacylated, acylated GHR and obestatin levels are differently inhibited by oral glucose load in pediatric obesity: Association with insulin sensitivity and metabolic alterations,” E Spen Eur. E. J. Clin. Nutr. Metab., vol. 6, no. 3, pp. e109-e115, 2011.
[34] V. Vicennati, S. Genghini, R. De Iasio, F. Pasqui, U. Pagotto U, et al. “Circulating obestatin levels and the GHR/obestatin ratio in obese women,” Eur. J. Endocrinol., vol. 157, no. 3, pp. 295-301, Sep. 2007.
[35] T. Reinehr, G. de Sousa, and C. L. Roth, “Obestatin and ghrelin levels in obese children and adolescents before and after reduction of overweight,” Clin. Endocrinol. (Oxf.), vol. 68, no.2, pp. 304-310, Feb. 2008.
[36] Z. F. Guo, X. Zheng, Y. W. Qin, J. Q. Hu, S. P. Chen, et al., “Circulating preprandial ghrelin to obestatin ratio is increased in human obesity,” J. Clin. Endocrinol. Metab., vol. 92, no. 5, pp.1875-1880, May. 2007.
[37] M. Anderwald-Stadler, M. Krebs, M. Promintzer, M. Mandl, M. G. Bischof, et al., “Plasma obestatin is lower at fasting and not suppressed by insulin in insulin-resistant humans,” Am. J. Physiol. Endocrinol. Metab., vol. 293, no. 5, pp.E1393-1398, Nov. 2007.
[38] P. B. Balagopal, S. S. Gidding, L. M. Buckloch, H. N. Yarandi, J. E. Sylvester, et al., “Changes in circulating satiety hormones in obese children: a randomized controlled physical activity-based intervention study,” Obesity, vol. 18, no. 9, pp. 1747-1753, Sep. 2010.
[39] C. C. Zou, L. Liang, C. L. Wang, J. F. Fu, and Z. Y. Zhao, “The change in ghrelin and obestatin levels in obese children after weight reduction,” Acta Paediatr., vol. 98, no. 1, pp. 159-165, Jan. 2009.
[40] H. Zamrazilová, V. Hainer, D. Sedlácková, H. Papezová, M. Kunesová, et al. “Plasma obestatin levels in normal weight, obese and anorectic women,” Physiol. Res., vol. 57, no.1, S49-55, 2008.
[41] D. G. Haider, K. Schindler, G. Prager, A. Bohdjalian, A. Luger, et al., “Serum retinol binding protein 4 is reduced after weight loss in morbidly obese subjects, J. Clin. Endocrinol. Metab., vol. 92, no. 3, pp. 1168-1171, Mar. 2007.
[42] P. Kravchun, O. Kadykova, A. Narizhnaya, O. Tabachenko, and O. Shaparenko, “Association of circulating adiponectin, resistin, irisin, nesfatin-1, apelin-12 and obestatin levels wıth hypertension and obesity,” Georgian Med. News, vol. 304-305, pp. 43-48, Jul.-Aug. 2020.
[43] A. S. Fittipaldi, J. Hernández, D. Castrogiovanni, D. Lufrano, P. N. De Francesco, et al. “Plasma levels of ghrelin, des-acyl ghrelin and LEAP2 in children with obesity: correlation with age and insulin resistance,” Eur. J. Endocrinol., vol. 182, no. 2, pp. 165-175, Feb. 2020.
[44] J. V. Gardiner, D. Campbell, M. Patterson, A. Kent, M. A. Ghatei, et al., “The hyperphagic effect of ghrelin is inhibited in mice by a diet high in fat,” Gastroenterology, vol.138, no. 7, pp. 2468-2476, 2476.e1, Jun. 2010.
[45] S. Barja-Fernández, J. Lugilde, C. Castelao, R. Vázquez-Cobela, L. M. Seoane, et al., “Circulating LEAP-2 is associated with puberty in girls,” Int. J. Obes. (Lond.), vol. 45, no. 3, pp. 502-514, Mar. 2021.
[46] W. Long, X. Xie, C. Du, Y. Zhao, C. Zhang, et al., “Decreased circulating levels of asprosin in obese children,” Horm. Res. Paediatr., vol. 91, no. 4, pp. 271-277, 2019.
[47] D. Corica, T. Aversa, M. Curro, A. Tropeano, G. Pepe, et al., “Asprosin serum levels and glucose homeostasis in children with obesity,” Cytokine, vol. 142, pp. 155477, Jun. 2021.
[48] M. S. Wen, C. Y. Wang, J. K. Yeh, C. C. Chen, M. L. Tsai, et al., „The role of asprosin in patients with dilated cardiomyopathy,” BMC Cardiovasc. Disord., vol. 20, no. 1, pp. 402, Sep. 2020.
[49] S. Wueest, and D. Konrad, “The controversial role of IL-6 in adipose tissue on obesity-induced dysregulation of glucose metabolism,” Am. J. Physiol. Endocrinol. Metab., vol. 319, no. 3, pp. E607-E613, Sep. 2020.
[50] B. H. Johnsen, G. Brattebø, T. M. Phillips, R. Gjeldnes, P. T. Bartone, et al., “Crossing the Antarctica: Exploring the effects of appetite-regulating hormones and indicators of nutrition status during a 93-day solo-expedition,” Nutrients, vol. 13, no. 6, pp. 1777, May 2021.
[51] M. Pourhassan, N. Babel, L. Sieske, T. H. Westhoff, and R. Wirth, “Inflammatory cytokines and appetite in older hospitalized patients,” Appetite, vol. 166, pp. 105470, Jun. 2021.
[52] A. Al-Shorman, B. AlKhatib, B. Abusalma, and H. Al-Domi, “The association between fat mass and subclinical atherosclerosis in healthy schoolchildren,” Clin. Nutr. ESPEN, vol. 37, pp. 87-92, Jun. 2020.
[53] A. Al-Shorman, H. Al-Domi, and A. Faqih, “Markers of subclinical atherosclerosis in schoolchildren with obesity and metabolic syndrome,” Swiss Med. Wkly., vol. 147, pp. w14446, Jun. 2017.
[54] H. Islam, L.K. Townsend, G. L. McKie, P. J. Medeiros, B. J. Gurd, et al., “Potential involvement of lactate and interleukin-6 in the appetite-regulatory hormonal response to an acute exercise bout,” J. Appl. Physiol., vol. 123, no. 3, pp. 614-623, Sep. 2017.
[55] S. Hunschede, R. Kubant, R. Akilen, S. Thomas, and G. H. Anderson, “Decreased appetite after high-intensity exercise correlates with increased plasma interleukin-6 in normal-weight and overweight/obese boys,” Curr. Dev. Nutr., vol.1, no. 3, pp. e000398, Feb. 2017.
[56] L. López-Ferreras, F. Longo, J. E. Richard, K. Eerola, O. T. Shevchouk, et al., “Key role for hypothalamic interleukin-6 in food-motivated behavior and body weight regulation,” Psychoneuroendocrinology, vol. 131, pp. 105284, Sep. 2021.
[57] N. H. Chamhuri, N. M. Tohit, A. Azzeri, N. Chamhuri, and S. R. M. Alias, “Age and fasting blood sugar levels are associated factors for mindful eating among Type 2 diabetes mellitus patients during COVID-19 pandemic confinement,” PLoS One, vol. 17, no. 9, pp. e0274327, Sep. 2022.